OGSIVEO is effective in reducing progression of desmoid tumors, improving disease control in adults with advancing cases.

Therapeutic Benefits:

OGSIVEO, as a gamma-secretase inhibitor, is used primarily for managing desmoid tumors. By inhibiting the Notch signaling pathway, it plays a role in modulating tumor growth and proliferation. Its therapeutic effect lies in slowing or halting the progression of desmoid tumors in patients who require systemic treatment. Given that desmoid tumors can be locally aggressive, OGSIVEO offers a systemic therapy option to control disease spread, potentially improving long-term outcomes for patients with advanced or progressive cases. Its ability to delay tumor progression is crucial in preserving quality of life and reducing surgical interventions.